Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. (MGTA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MGTA · as of Jun 9, 2026
Key Statistics
Explore Magenta Therapeutics, Inc. Data
mgta stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 10 · Buy rate: 40.0%
Competitors & Peers
mgta competitorsMGTA
ALVR
BLUE
EYEN
GRNA
LUMOStock Performance
Full HistoryAbout Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for indiv…
what is magenta therapeutics, inc. · mgta stock overview · magenta therapeutics, inc. company profile · who is magenta therapeutics, inc. ceo · mgta NASDAQ · magenta therapeutics, inc. headquarters · magenta therapeutics, inc. business segments
About Stock Overview & Key Data
Magenta Therapeutics, Inc. (MGTA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 21, 2018. As of the latest trading session, MGTA stock price is $0.70, with a market capitalization of $42.4M. The stock has returned -35.82% over the past 12 months and +70.63% year-to-date.
According to 10 Wall Street analysts, the consensus rating for Magenta Therapeutics, Inc. stock is Hold, with an average 12-month price target of $—. In fiscal year 2025, Magenta Therapeutics, Inc. reported revenue of $2.0M and net income of -$162.3M. For detailed data — including Magenta Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Magenta Therapeutics, Inc. (MGTA) stock price is $0.70. The stock is traded on NASDAQ under the ticker symbol MGTA. The 52-week range is $0.32 – $1.81.